Much discussion in the corporate blawgosphere of Selectica, Inc. v. Versata Enterprises, Inc. VC Noble's opinion for the Delaware Chancery Court involved what Steven Davidoff calls "frankly odd" facts:
They arose out of Versata’s acquisition of 5.2 percent of Selectica and Versata’s accompanying offer to acquire Selectica. (Both companies produce business software.) In response, Selectica adopted a low-threshold, net-operating-loss poison pill that would be triggered when someone acquired 4.99 percent of its stock, rather than the more typical 15 percent trigger. Versata was exempted from this threshold to the extent that it did not subsequently acquire Selectica shares.
The net operating loss poison pill is a new development. The lower triggering threshold is adopted to conform with Section 382 of the Internal Revenue Code and protect the company’s net operating losses, which can be used to lower future taxes to the extent a company accrues profits. According to Factset Sharkrepellent, 41 companies including Citigroup and Pulte Homes adopted these types of pills last year. Selectica itself is a microcap survivor of the dot.com bubble with $160 million of net operating losses, a market capitalization of about $11 million, little revenue and no profits. It is uncertain whether Selectica will ever return to profitability in order to use these net operating losses, or N.O.L.s, as the court refers to them.
A post by Kevin Brady reviews the facts in much greater detail and also provides a through review of the legal analysis.
How does the NOL pill work? A Wachtell Lipton client memo explains that: